Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000622 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
NCT02000622 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 302 participants.
The verdict
NCT02000622, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
Study Summary
This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.
Interventions
- DRUG Olaparib
- DRUG Physician's choice chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2014-03-27 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000622
The ClinicalTrials.gov registry entry for NCT02000622 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT02000622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02000622 about?
NCT02000622 is a clinical study titled "Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.". This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.
What is the current status of trial NCT02000622?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2014-03-27. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT02000622?
The interventions under investigation include: Olaparib (DRUG), Physician's choice chemotherapy (DRUG).
Who is sponsoring clinical trial NCT02000622?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.